Ascidian Therapeutics

We invite you to tune in to "Rare Insights" on Monday July 29th to hear from our own Dr. Jay Barth about all things #RNAExonEditing and our groundbreaking lead program in #StargardtDisease. Thanks for providing your insights, Jay, and thank you Taren Grom and Know Rare for sharing important information about RNA editing in rare disease research.

✔ Deep understanding of disease pathology ✔ Commitment to novel modalities ✔ Excellent clinical development ✔ Novel delivery strategies   “Roche ticked all those boxes”   ICYMI - check out Hannah Green's article in the Boston Business Journal for more about how we’re combining Ascidian’s #RNA exon editors with the next generation #CNS delivery capabilities of Roche. Thanks for speaking with us, Hannah! 👉 https://lnkd.in/e5-WeiUc

#ICYMI, check out this BioWorld News article by Karen Carey about some of the most recent and biggest biotech deals – including our new collaboration with Roche. In it, Michael Ehlers and Daniel Rosan share insights about why Ascidian and Roche are ideal partners, and what we have the potential to achieve together.   Thanks, Karen for breaking down the deal and the science behind it for your readers 👉 https://lnkd.in/e4Uhn9SA

“A first big pharma partnership for Ascidian, headed up by ex-Biogen research head Michael Ehlers, as [Roche] expands its gene editing and neuroscience efforts.” Thanks, Andrew McConaghie and Citeline/Scrip for sharing the news and explaining why we believe #RNA #ExonEditing could “create therapies for conditions not amenable to existing gene therapy and gene-editing technologies.” 👉 https://lnkd.in/evcDNtff  

Check out Helena Smolak's The Wall Street Journal/Dow Jones article to learn how our deal with Roche is “complementary to Roche's own gene editing strategy and aims to benefit its neuroscience portfolio...” 👉 https://lnkd.in/eS3Q56AH #RewritingRNA #RNAExonEdting #Neurocience #GeneTherapy

Thanks, Tyler Patchen and BioSpace for your article about our new collaboration with Roche. As part of your #NextGenClassof2024, we’re proud to be giving you more to watch this year! Read more here 👇 https://lnkd.in/ef5i8huR

Thank you, Genetic Engineering & Biotechnology News for covering our new partnership with Roche and capturing our insights about how the collaboration could overcome several challenges to treating neurological conditions. 👉 https://bit.ly/3XphcDz

“Ascidian’s progress with its lead internal program helped accelerate discussions...” Check out Frank Vinluan's MedCity News article for more about what led to our partnership with Roche and where we’re headed. It was a pleasure to speak with you, Frank! 👉 https://bit.ly/45B3pMf

More than anything, we appreciate connecting with the communities we aim to serve. Thank you Foundation Fighting Blindness for hosting #VISIONS24 and giving us an opportunity to share the latest updates on our science with individuals and families affected by blinding diseases.  #RNAExonEditing #StargardtDisease Robert Bell

“Our partnership with Ascidian is an opportunity to harness advanced RNA exon editing technology, which has the potential to deliver transformative one-time therapeutics by editing multiple whole exons at the RNA level with a single treatment," said Roche’s James Sabry in this Reuters piece by Pratik Jain. Read more 👉 https://reut.rs/4b80HyL #RNAExonEditing #Neuroscience